Custo G M, Carenza L, Pala A
Contraception. 1980 Mar;21(3):311-7. doi: 10.1016/0010-7824(80)90009-8.
Twelve subjects using the intrauterine progesterone system were followed during 4 consecutive menstrual cycles for FSH, LH, hCG and progesterone levels. They were all multiparous, with documented ovulation and sexually active even during the ovulatory period. With the exception of one case which became pregnant, there was no evidence for the presence of hCG during the period of observation. This data, even if preliminary, suggest that the Progestasert(TM) exerts a contraceptive action which differs from that of other devices, whether medicated or not, and that, such action occurs at a stage early enough to prevent the formation of hCG.
对12名使用宫内孕酮系统的受试者进行了连续4个月经周期的跟踪,检测其促卵泡生成素(FSH)、促黄体生成素(LH)、人绒毛膜促性腺激素(hCG)和孕酮水平。她们均为经产妇,有排卵记录,即使在排卵期也有性生活。除1例怀孕外,观察期间未发现hCG存在的证据。这些数据即使是初步的,也表明Progestasert(商标名)发挥的避孕作用不同于其他器械,无论其是否含药,且这种作用发生在足够早的阶段以阻止hCG的形成。